ISRCTN96013814已完成未知
A randomized, double-blind, placebo controlled, four-period, cross-over study to evaluate the cognitive effects of single oral administration of roflumilast in age-associated memory impairment
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
2019 results in: https://doi.org/10.1016/j.neurobiolaging.2019.01.014
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements
- •2. Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures
- •3. Healthy adult as judged by Medical Supervisor
- •4. Aged 60 to 80 years, inclusive, at the time of informed consent
- •5. Memory performance between 1 to 2 SD below (for Impaired Elderly) and between 0.5 SD below and 0.5 SD above (for Healthy Elderly) age, gender, and education level corrected normative values assessed using the VLT
- •6. The subject has normal hearing demonstrated by average audiometric hearing thresholds of 20 dB hearing level (HL) and relatively symmetric hearing (left/right ear asymmetry of 15 dB)
- •7. Body mass index (BMI) between 18 and 30 kg/m2 inclusive at Screening
- •8. A male subject who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last dose
- •9. A female subject of childbearing potential who is sexually active with a nonsterilized male partner agrees to use acceptable methods of contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last dose
- •10. Clinical laboratory evaluations (including clinical chemistry, hematology and complete urinalysis) within the reference range for the testing laboratory, unless the results are deemed not to be clinically significant (CS) by the investigator or sponsor at screening and Day 1 of Period 1
排除标准
- •1. Received any investigational compound within 30 days prior to the first dose of study medication
- •2. Received roflumilast in a previous clinical study or as a therapeutic agent
- •3. Immediate family member, study site employee, or in a dependant relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress
- •4. Uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality which may impact the ability of the subject to participate or potentially confound the study results
- •5. Previous or existing major psychiatric symptoms (evaluated through semi- Structured Clinical Interview for DSM MINI for the assessment of lifetime DSM-IV Axis -II diagnoses)
- •6. Known hypersensitivity to any component of the formulation of roflumilast or related compounds
- •7. Positive urine drug result for drugs of abuse at Screening Visit 2
- •8. History of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the screening visit or is unwilling to agree to abstain from alcohol from 72 hrs prior to Day 1 through Day 2 of each Period and/or drugs throughout the study
- •9. Taken any excluded medication, supplements, or food products listed in the Excluded Medications and Dietary Products table listed in Section 7.3
- •10. Evidence of uncontrolled cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the subject’s medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking roflumilast or a similar drug in the same class, or that might interfere with the conduct of the study as judged by Medical Supervisor. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias.
- •11. Current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis frequent [more than once per week] occurrence of heartburn, or any surgical intervention [eg, cholecystectomy, bariatric surgery])
- •12. History of cancer within the past 5 years prior to the first dose of study medication. This criterion does not include those subjects with basal cell or stage I squamous cell carcinoma of the skin who are eligible.
- •13. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV), human immunodeficiency virus (HIV) antibody/antigen at Screening
- •14. Used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) greater than the equivalent of 10 cigarettes per day during the one month prior to study start
- •15. Ppoor peripheral venous/arterial access
- •16. Donated or lost 450 mL or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 3 mo
研究者
相似试验
已完成
不适用
Chinese herbal medicine in the treatment of women with recurrent urinary tract infectionsTopic: Primary CareSubtopic: Infectious diseases and microbiology, Primary careDisease: All DiseasesInfections and InfestationsISRCTN95402719niversity of Southampton (UK)61
已完成
不适用
Studying the impact of Doxycycline on fear memory in healthy individualsISRCTN66987216Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)160
已完成
2 期
A randomised, double blind, placebo-controlled, phase 2a study of the efficacy, safety and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexateRheumatoid arthritisISRCTN49455679Academic Medical Center (AMC) (The Netherlands)191
已完成
不适用
A randomised, double blind, placebo-controlled study of the effects of Dehydroepiandrosterone (DHEA) replacement on vascular function in patients with primary and secondary adrenal insufficiencyISRCTN46268487Cardiff University (UK)40
已完成
不适用
Safety and Efficacy of Loxoprofen Sodium cataplasm Ointment Against Myalgia (SELSOAM)ISRCTN16227145ead Chemical Co. Ltd (Japan)160